Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author's Response to: Comment on "Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM Database" and "Critical Evaluation of Methodological Approaches in ALK TKI Research: Addressing Confounding Factors and Statistical Robustness".
Parikh K. Parikh K. J Thorac Oncol. 2024 Nov;19(11):e66-e67. doi: 10.1016/j.jtho.2024.08.025. J Thorac Oncol. 2024. PMID: 39510710 No abstract available.
Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.
Parikh K, Dimou A, Leventakos K, Mansfield AS, Shanshal M, Wan Y, Lin HM, Vincent S, Elliott J, Bonta IR. Parikh K, et al. J Thorac Oncol. 2024 Nov;19(11):1539-1549. doi: 10.1016/j.jtho.2024.07.009. Epub 2024 Jul 15. J Thorac Oncol. 2024. PMID: 39019326 Free article.
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Nassar AH, et al. Among authors: parikh k. J Thorac Oncol. 2024 Sep 10:S1556-0864(24)02265-2. doi: 10.1016/j.jtho.2024.09.1379. Online ahead of print. J Thorac Oncol. 2024. PMID: 39260522
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Nassar AH, et al. Among authors: parikh k. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. J Thorac Oncol. 2024. PMID: 38278303
Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Desai A, et al. Among authors: parikh k. Clin Lung Cancer. 2023 Dec;24(8):689-695.e1. doi: 10.1016/j.cllc.2023.09.001. Epub 2023 Sep 17. Clin Lung Cancer. 2023. PMID: 37880074 Free article.
Editorial: Insights in thoracic oncology: 2021/2022.
Parikh K, Addeo A. Parikh K, et al. Front Oncol. 2022 Dec 2;12:1089540. doi: 10.3389/fonc.2022.1089540. eCollection 2022. Front Oncol. 2022. PMID: 36531054 Free PMC article. No abstract available.
Cellular Therapy in NSCLC: Between Myth and Reality.
Imbimbo M, Wetterwald L, Friedlaender A, Parikh K, Addeo A. Imbimbo M, et al. Among authors: parikh k. Curr Oncol Rep. 2023 Oct;25(10):1161-1174. doi: 10.1007/s11912-023-01443-z. Epub 2023 Aug 30. Curr Oncol Rep. 2023. PMID: 37646900 Free PMC article. Review.
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
Nassar AH, El Zarif T, Khalid AB, Rahme S, Zhong C, Kwak L, Salame M, Farhat EB, Freeman D, El-Am E, Ravishankar A, Ahmad B, Nana FA, Kaldas D, Naqash AR, Sharon E, LeBoeuf NR, Cortellini A, Malgeri A, Gupta S, Al-Hader A, Sparks JA, Linnoila J, Hamnvik OR, Mouhieddine TH, Marron T, Parikh K, McKay RR, Dilling T, Choueiri TK, Adib E, Najem E, Kim SY, Sonpavde G. Nassar AH, et al. Among authors: parikh k. J Immunother Cancer. 2024 Mar 5;12(3):e008724. doi: 10.1136/jitc-2023-008724. J Immunother Cancer. 2024. PMID: 38448038 Free PMC article.
Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study.
Nassar AH, El-Am E, Denu R, Abou Alaiwi S, El Zarif T, Macaron W, Abdel-Wahab N, Desai A, Smith C, Parikh K, Abbasi M, Bou Farhat E, Williams JM, Collins JD, Al-Hader A, McKay RR, Malvar C, Sabra M, Zhong C, El Alam R, Chehab O, Lima J, Phan M, Dalla Pria HF, Trevino A, Neilan TG, Kwan JM, Ravi V, Deshpande H, Demetri G, Choueiri TK, Naqash AR. Nassar AH, et al. Among authors: parikh k. JACC CardioOncol. 2024 Jan 16;6(1):71-79. doi: 10.1016/j.jaccao.2023.11.007. eCollection 2024 Feb. JACC CardioOncol. 2024. PMID: 38510282 Free PMC article.
552 results